The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application for enzalutamide (XTANDI) as the first androgen receptor signaling inhibitor for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). With this approval, patients with nmCSPC and high-risk BCR may now be treated with enzalutamide with or without a gonadotropin-releasing hormone (GnRH) analog therapy. ...
Localized
Advertisement
Latest News
PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP.
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Enzalutamide combined with leuprolide led to higher rates of MFS than leuprolide alone.
ArteraAI Prostate—a multimodal, AI-derived prognostic test—was successfully validated in the phase 3 STAMPEDE trials.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
Advertisement
Trending
The authors said that “PDEARGs are valuable prognostic predictors and potential therapeutic targets” for patients with ...
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Advertisement
